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Abstract
Background: Muscle disease associated with different etiologies has been shown to produce localized
accumulations of amyloid and oxidative stress-related proteins that are more commonly associated with
neurodegeneration in the brain. In this study we examined changes in muscle tissue in a classic model of diabetes
and hyperglycemia in rabbits to determine if similar dysregulation of Alzheimer Ab peptides, the prion protein
(PrP), and superoxide dismutase 1 (SOD1), as well as nitric oxide synthases is produced in muscle in diabetic
animals. This wild-type rabbit model includes systemic physiological expression of human-like Alzheimer precursor
proteins and Ab peptides that are considered key in Alzheimer protein studies.
Results: Diabetes was produced in rabbits by injection of the toxic glucose analogue alloxan, which selectively
enters pancreatic beta cells and irreversibly decreases insulin production, similar to streptozotocin. Quadriceps
muscle from rabbits 16 wks after onset of diabetes and hyperglycemia were analyzed with biochemical and in situ
methods. Immunoblots of whole muscle protein samples demonstrated increased PrP, SOD1, as well as neuronal
and inducible Nitric oxide synthases (NOS1 and NOS2) in diabetic muscle. In contrast, we detected little change in
Alzheimer Ab precursor protein expression, or BACE1 and Presenilin 1 levels. However, Ab peptides measured by
ELISA increased several fold in diabetic muscle, suggesting a key role for Ab cleavage in muscle similar to
Alzheimer neurodegeneration in this diabetes model. Histological changes in diabetic muscle included localized
accumulations of PrP, Ab, NOS1 and 2, and SOD1, and evidence of increased central nuclei and cell infiltration.
Conclusions: The present study provides evidence that several classic amyloid and oxidative stress-related disease
proteins coordinately increase in overall expression and form localized accumulations in diabetic muscle. The
present study highlights the capacity of this wild-type animal model to produce an array of hallmark pathological
features that have also been described in other muscle diseases.
Background
Muscle disease has been linked with aging as well as
metabolic conditions, which prominently includes dia-
betes [1-4]. In diabetes, weakness, wasting, and pain
have been cited which commonly occur in quadriceps
muscles. Muscle disease has been studied in a variety of
conditions including animal models of high dietary cho-
lesterol [5], pathological response to the drug chloro-
quine [6,7], and inclusion body myositis [8]. Each of
these muscle conditions has been shown to produce
localized accumulations of PrP and Ab peptides, as well
as superoxide dismutase 1 (SOD1) and Nitric oxide
synthases 1 and 2 (NOS1: neuronal nNOS; and NOS2:
inducible iNOS) [9,10]. These proteins are more often
thought of in the context of neurodegenerative diseases
(PrP, mad cow disease; Ab, Alzheimer disease (AD); and
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SOD1, Amyotrophic lateral sclerosis (ALS)/Lou Gehrig’s
disease). However, these proteins have also been linked
with diabetes. For example, strong associations between
AD and diabetes has led to use of the term ‘Type III
diabetes’ for AD [11]. More recently, extensive epide-
miological data linking AD and diabetes are now sup-
ported by direct mechanistic links between Ab peptide
action and insulin receptor dysfunction in cells. Ab pep-
tides form small diffusible oligomers that can interact
directly with insulin receptors (IR) on cell surfaces. This
can lead to coordinate endocytosis of Ab/IR complexes,
and intracellular co-localization, which has been shown
in cultured cells. Moreover, this process has also been
linked with insulin resistance [12,13]. Evidence for a
role for these amyloid disease proteins in muscle disease
also comes from transgenic models, where muscle-
specific expression of PrP, Ab or SOD1 also produced
localized accumulation. In addition, these muscle disease
models also showed evidence of central nuclei and cell
infiltration [14-19].
Deleterious activities attributed to these disease pro-
teins is linked with an ability to produce oxidative stress,
and also to form oligomers and aggregates in brain,
muscle, and lens, as well as pancreas during onset and
progression of Type II diabetes [20-25]. Diabetes and
hyperglycemia increase systemic and tissue-specific oxi-
dative stress loads. Consistent with this, increases in glu-
cose oxidation products have been measured in muscle
as well as in the circulatory system in diabetic animals
[26,27]. Classic oxidative stress responses include stimu-
lation of stress signaling pathways and activation of
genes linked with stress and also cell proliferation, in
part due to the activation of AP1 and NFB stress-
responsive transcription factors [28-30]. Previously, our
laboratory also demonstrated PrP and Alzheimer Ab
Precursor Protein (AbPP) gene expression increase sig-
nificantly during a response to oxidative stress [31-33].
Stress in tissues that include muscle can be aggravated
by diabetes and high glucose that contributes to
increased amyloid and oxidative stress-related protein
expression and formation of protein deposits as well as
producing further oxidative stress. In addition, stress
signaling can affect normal cell migration and trophic
responses [31,34].
In the present study we examined expression of PrP,
AbPP and Ab, SOD1, NOS1 and NOS2 in muscle in
4 month-old wild-type (wt) rabbits induced to become
diabetic and hyperglycemic with alloxan. This model has
been used to model diabetic complications in >500 stu-
dies over the past 50 yrs. Unlike mice and rats, wt rab-
bits produce Ab peptides with the same sequence as
humans. Mouse and rat Ab has lower metal affinity that
limits its ability to form oligomers and also to produce
oxidative stress [20-23]. Like streptozotocin, alloxan is a
toxic glucose analogue that selectively enters pancreatic
b-cells via Glut2 glucose transporters, which are not
expressed in muscle [35-37]. Alloxan forms toxic reac-
tive oxygen species in pancreatic b-cells, and irreversibly
decreases insulin production. Consistent with these
activities, alloxan has a short half-life (~1.5 min), and is
cleared quickly. Here, we examined quadriceps from
diabetic and normal control rabbits 16 weeks after onset
of diabetes and hyperglycemia. Studies of diabetic com-
plications in other organs using this model indicated a
time frame of 4-6 mos produced substantial effects
[38,39]. We identified substantial increases in PrP,
SOD1, NOS1, and NOS2 expression on immunoblots of
total muscle protein samples from diabetic animals, and
ELISA assays measured several fold increases in Ab pep-
tides produced in diabetic muscle. Consistent with those
findings, in situ examination of diabetic and control
muscle identified localized accumulations of each of
these proteins in muscle sections from diseased animals,
and also identified muscle fibers with central nuclei and
evidence of cell infiltration.
Methods
Production of diabetes and hyperglycemia in rabbits
New Zealand white rabbits (Covance) were used in
accordance with NIH guidelines and approved protocols.
All rabbits were males to limit hormonal effects at this
stage of our studies. 3-4 month-old rabbits were housed
at RT° with a 12 hr light/12 hr dark cycle, and fed 260
gm/day of a standard pellet diet with free access to
dH2O. Seven rabbits were given 150 mg/kg alloxan
(Sigma) in a single injection through a catheter in an
ear vein and six untreated rabbits were used as normal
controls. During the initial 24 hrs after alloxan, 10% glu-
cose in dH2O was given to reduce adverse effects. After
one week, rabbits exhibiting a consistent elevation in
blood glucose (> 350 mg/dl) remained in the study.
Normal blood glucose in control rabbits was ~100 mg/
dl, and blood glucose was monitored prior to feeding
each morning. At the start of this study, rabbits weighed
~2.5 kg. After 16 wks, rabbits were taken for analysis.
Diabetic rabbits gained an average of 225 gm (s.d. 180
gm) and control rabbits gained on average 500 gm (s.d.
50 gm), with no rabbits losing weight.
Immunohistochemistry and Immunofluorescence
Paraffin sections were prepared from buffered 4% paraf-
ormaldehyde fixed muscle tissues. Sections were de-
waxed in xylenes and graded alcohol washes, and
blocked in PBS with 10% serum corresponding to the 2°
antibody used. For immunofluorescence detection, fluor-
conjugated 2° antibodies (Invitrogen) were used to
visualize complexes. Immunohistochemical staining used
horseradish peroxidase Vectastain kits (Vector labs).
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Antibodies included: mouse mAb anti-PrP (Cayman
Chemical Co.), rabbit mAb anti-PrP (Epitomics), 6E10
and 4G8 mAb anti-Ab (Covance), rabbit anti-AbPP
(Sigma), sheep polyclonal anti-SOD1 (CalBiochem) and
mouse mAb anti-SOD1 (Thermo), mouse mAb anti-
NOS1 and anti-NOS2 (BD Biosciences).
Immunoblot detection of proteins
Samples of total protein from quadriceps muscle from
diabetic and normal control animals were homogenized
in SDS sample buffer with reducing agent and protease
inhibitors (Calbiochem), for electrophoresis on Bis-Tris
gels (Invitrogen). Proteins resolved by molecular weight
were blotted to PVDF filters, and blocked in 5% non-fat
milk in PBS pH 7.4. Filters were probed overnight with
antibodies diluted in PBS according to the supplier.
HRP conjugated 2° antibodies (Jackson Labs) were used
to visualize complexes with chemiluminescence kits on
films (Amersham).
ELISA assays
To quantify Ab peptide levels in muscle tissue, ELISA
kits (Covance) specific for Ab peptides ending at amino
acid 42 or amino acid 40 were used (x-42; x-40). These
standard sandwich ELISAs used a primary antibody that
recognized the Ab peptides’ C-terminus and distin-
guished Ab40 from Ab42, and the secondary antibody
recognized an internal peptide epitope. Controls and
standard curves were prepared as directed by the sup-
plier. 150 mg of muscle tissue from experimental and
control animals was solubilized in 5 M Guanidine buf-
fer, and colorimetric quantification of HRP reaction pro-
duct linked to antibody-antigen complexes was
measured with a standard spectrometer plate reader.
ELISA assays were performed three times for x-40 and
x-42 Ab peptides. A statistical power analysis indicated
that three rabbits are theoretically required to provide
sufficient power for this study, and this was also true
when accounting for several fold differences we mea-
sured in our assays http://www.dssresearch.com/toolkit/
sscalc/size.asp. For the ELISAs, the p-values were calcu-
lated using a 2-tailed ANOVA statistical test.
Results
PrP, Ab, SOD1, NOS1 and NOS2 overall expression
increases in total muscle protein samples from diabetic
rabbits
Rabbits injected with alloxan became hyperglycemic
and maintained blood glucose levels >350 mg/dl. After
16 weeks of elevated blood glucose levels, we took
quadriceps muscle samples for analysis. We examined
changes in overall expression of PrP, SOD1, NOS1,
and NOS2, and for AbPP and Ab peptide products in
total muscle protein from diabetic and control animals.
We first probed immunoblots with antibodies raised
against PrP to determine if changes in expression
occurred in diabetic muscle. mAb anti-Prion antibody
(and rabbit polyclonal Ab; not shown) identified a sig-
nificant increase in expression of PrP in diabetic mus-
cle (Fig. 1A). These findings also agreed with in situ
detection of PrP protein in muscle described below.
We observed a protein doublet on immunoblots of
total protein from experimental and control animals,
and it appears to correspond with single glycosylated
forms described in the literature [40]. Densitometric
analysis of films after chemiluminescence detection of
proteins indicated a ~3-fold increase in PrP expression
occurred in diabetic muscle compared with normal
controls (Fig. 1C). We next examined SOD1 protein
expression in diabetic and control muscle, and
detected >2-fold increase in SOD1 in muscle from dia-
betic animals on immunoblots (Fig. 1A), which was
also consistent with our analysis of SOD1 accumula-
tion described below. However, when we examined
AbPP we did not see any significant changes in expres-
sion in normal vs. diabetic muscle (Fig. 1A). This find-
ing was consistent with in situ analysis of AbPP
protein expression (not shown), but differs from mea-
surements of Ab peptides produced in diabetic muscle
described below. When we probed immunoblots with
antibodies directed against the b-acting cleaving
enzyme 1 and presenilin 1 protease that generate Ab
peptides, we did not observe substantial shifts in the
levels of either protein, similar to our examination of
amyloid and oxidative stress related PrP, SOD1, and
NOS proteins in diabetic muscle. However, it is known
that other factors including production of alternatively
spliced AbPP isoforms [41] can influence Ab levels.
Deleterious effects of nitric oxide in disease are
thought to involve reactive NO species that can form
via NO interactions with molecular oxygen or superox-
ide radicals [42]. In addition, deleterious increases in the
level of NO also induce nitrosative stress and stimulate
cellular pathways that contribute to protein S-nitrosyla-
tion and denitrosylation involving metalloproteins [43].
Increased expression and accumulation of Nitric oxide
synthases 1 and 2 has been observed in muscle and
brain diseases that are also associated with these amy-
loid proteins which are capable of producing oxidative
stress [44]. When we examined changes in NOS1 and
NOS2 protein levels in diabetic muscle on immunoblots,
we identified a ~2-fold increase in NOS1 and NOS2 in
total protein samples (Fig. 1B). NOS1 was detected
more strongly in control muscle than NOS2, where
NOS2 was barely detected in normal control muscle in
our assays.
When we next examined Ab peptide levels in normal
and diabetic muscle, we measured quite substantial
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increases in Ab peptides from diseased muscle using
more quantitative ELISA methods. Ab peptides are
cleaved from the parent AbPP protein by b- and g-
secretases. Presenilin proteins are a key component of
g-secretase protease activity that cleaves Ab at its C-ter-
minus and is responsible for producing Ab peptides
ending at amino acid 40 or 42 [45]. In Alzheimer neuro-
degeneration, both Ab 1-40 and 1-42 peptides increase
in brain. However, Ab 1-42 peptides are considered
more deleterious in part due to greater metal affinity,
which allows them to more readily form oligomers and
produce hydrogen peroxide [23]. To measure Ab pep-
tides in diabetic muscle vs. normal controls, we used dif-
ferent ELISA assays that were specific for Ab peptides
ending at amino acid 40 or ending at 42. These assays
do not detect the full length AbPP parent protein. Using
these more quantitative methods, we measured ~7-fold
more Ab x-40, and a slightly higher increase of Ab x-42
in muscle from diabetic animals compared to controls
(Fig. 2). These increases also agreed with in situ detec-
tion using different Ab specific antibodies, described
below.
Figure 1 Increased expression of the Prion Protein (PrP), Superoxide dismutase 1 (SOD1), and Nitric oxide synthases 1 and 2, but not
the Alzheimer Ab precursor protein (AbPP), Presenilin 1 or BACE1 occurs in total muscle protein from diabetic rabbits. Immunoblot
detection of proteins in diabetic and control muscle. A: PrP (MW ~30kDa, Epitomics), SOD1 (MW ~16kDa, Calbiochem), AbPP (MW ~110 kDa,
Sigma), B: NOS1 (MW ~160 kDa, BD Biosciences), NOS2 (MW ~130 kDa, BD Biosciences), Presenilin 1 (MW ~52 kDa, Santa Cruz), BACE1 (MW
~55kDa, Santa Cruz) in total protein samples of quadriceps muscle from normal control (Con) and diabetic (Diab) rabbits. The doublet protein
bands for PrP in diabetic and normal control muscle in Panel A is consistent with glycosylated forms, C: Densitometry measurements of protein
bands shown on immunoblots above. Bar graphs show averages of the two band intensities with standard deviations. (NC: normal controls;
D: diabetic).
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Local accumulations of amyloid and oxidative stress-
related proteins as well as disorganized fibers, occur in
muscle in diabetic animals
Studies that examined muscle disease in animal models
as well as in transgenic mice expressing amyloid and
stress-related proteins in muscle, identified accumula-
tions of these amyloid and oxidative stress proteins, pre-
dominantly with in situ methods. Similar protein
deposits have also been observed in conditional trans-
genic mice induced to express these proteins in mature
animals. We began our in situ analysis by examining
fiber cell histology in hematoxylin and eosin stained sec-
tions. Regions in diabetic muscle contained disorganized
fibers with swollen regions in muscle fibers (Fig. 3). In
addition, muscle fibers were also observed that had cen-
tral nuclei, and fibers surrounded by numerous hema-
toxylin stained nuclei suggestive of cell infiltration.
When we probed sections with specific antibodies to
determine the distribution of PrP, SOD1, Ab and NOS1
and NOS2 in muscle from diabetic and control animals,
we identified areas with localized accumulations for
each of these proteins, consistent with the in vitro bio-
chemical assays described above. We first probed sec-
tions with 6E10 and 4G8 monoclonal anti-Ab antibodies
(Fig. 4). These antibodies recognize epitopes in Ab pep-
tides that differ from those used in our ELISA assays.
Both of these antibodies identified areas within muscle
fibers that contained increased Ab concentrations, and
agreed with ELISAs. Likewise, muscle sections probed
with antibodies raised against SOD1, PrP, NOS1, and
NOS2 also identified regions with significant protein
accumulation in muscle fibers from diabetic animals,
also consistent with immunoblot assays (Figs. 4).
In addition, when we probed muscle sections with
antibodies to detect two of these proteins, we observed
overlapping distributions of these proteins in muscle
fiber deposits (Fig. 4).
Discussion
In the present study we demonstrated that several clas-
sic amyloid and oxidative stress-related disease proteins
increase in overall expression and produce localized
accumulations in quadriceps muscle in diabetic rabbits
in our wt animal model. We also identified histopathol-
ogy that included the presence of central nuclei in mus-
cle fibers and increased cell infiltration, also described
in other muscle diseases and models. Our results indi-
cate that stress produced during the onset and progres-
sion of diabetes and hyperglycemia induced in mature
animals stimulates the expression of these proteins
throughout the muscle. However, future studies are
needed to determine the factors and processes involved
in producing focal accumulations of these proteins in
muscle fibers in diabetic animals. Our study determined
that significant pathology was produced at 16 weeks in
unmanaged diabetes and hyperglycemic animals in our
model, and further studies can determine the relation-
ship and onset of pathology associated with each of
these proteins.
Our experiments that analyzed Ab peptides used sev-
eral antibodies that each identified increased production
of Ab in diabetic muscle. ELISA assays measured
~7-fold increases in Ab peptides in total muscle protein
samples. These assays used primary antibodies that
recognized presenilin/g-secretase cleavage sites at amino
acid 40 or 42, and a common secondary antibody that
recognized an epitope several amino acids from the Ab
C-terminus. As a result, these assays have the capability
Figure 2 ELISA assays measuring increased levels of Alzheimer Ab peptides in diabetic muscle. Levels of Alzheimer Ab peptides ending
at amino acid 40 (x-40) or 42 (x-42) were determined in total muscle proteins from three diabetic and three normal control rabbits. ~7.5-fold
increases were measured for Ab40 and Ab42 peptides in diabetic muscle compared to normal control muscle (P < 0.0005 and P < 0.0025,
respectively). Graphs show pg/ml of Ab detected in muscle samples determined using standard peptide controls (Covance). Graphs show mean
values of 3 diabetic and 3 control animals with standard deviations.
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to measure a variety of peptide lengths that are cleaved
at a g-secretase site at one end. Antibodies used in
our in situ Ab analysis detected epitopes close to the
N-terminus, and also identified increased Ab in deposits
in diabetic muscle. Although these antibodies can poten-
tially detect the AbPP parent protein, we did not
observe increased AbPP expression in vitro or in muscle
sections with AbPP specific antibodies. Together, these
findings indicate increased Ab in diabetic muscle is lar-
gely the result of increased proteolytic Ab cleavage.
These observations are consistent with studies on Ab
production in the brain, where Ab production in that
organ has not been shown to correspond with signifi-
cant changes in AbPP levels either. In addition, these
observations in muscle are supported by findings in
transgenic mice that showed transgenic co-expression of
presenilin with AbPP in muscle also leads to enhanced
Ab production.
Each of the proteins examined here is linked with
oxidative stress as well as with protein misfolding dis-
ease mechanisms. Studies of amyloid protein structure
in neurodegenerative disease indicated these proteins
can act synergistically to produce insoluble aggregates.
For example, pathological changes in PrP structure can
contribute to misfolding of other PrP proteins, and can
also influence folding of nearby Ab peptides in neu-
rons [46]. The present finding of overlapping protein
accumulations in diabetic muscle suggests similar
interactions may also contribute to protein deposits
containing multiple proteins in diabetic muscle. In
addition, examination of the relative order and rate of
production for each of these disease-related proteins at
earlier stages after onset of diabetes and hyperglycemia
in this model can also help sort out relative contribu-
tions of each protein in the formation of deposits in
muscle fibers.
Figure 3 Histological features generally characteristic of muscle degeneration linked with a variety of conditions are produced in
quadriceps muscle from diabetic, hyperglycemic rabbits. Hematoxylin and eosin stained muscle sections from diabetic (A-F, H) and control
(G, I) rabbits demonstrating central nuclei (A, H) and showing evidence of cell infiltration (A, C, F), not seen in normal control muscle. Muscle
fiber cross-sections are ~40-50 μm in diameter. Images are representative of 3 diabetic and 3 control animals.
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The present findings demonstrating a similar set of
proteins accumulate in muscle fibers in this diabetes
model as in other muscle disease conditions discussed
above, is also supported by gene array studies that
examined global gene expression changes in different
models of muscle disease. Microarray experiments com-
paring expression profiles in muscle disuse, cachexia,
repetitive stress, and diabetes in streptozotocin treated
animals, found common changes in overall expression
patterns and specific pathways in these disease models
[47,48]. These observations also indicate similar path-
ways are triggered in a spectrum of muscle conditions.
However, we speculate increased expression that pro-
duces substantial localized accumulations of Ab, SOD1,
PrP and NOS1 and NOS2 in a number of muscle dis-
ease conditions, suggests these proteins have a promi-
nent and early role that is shared in muscle conditions
linked with different modes of physiological stress.
Increased NOS expression and NO production is linked
with nitrative and nitrosative stress. Together with reac-
tive oxygen species produced in non-enzymatic glycation
reactions in diabetes, increased NO can react with
superoxides to form peroxynitrite which is also a highly
reactive oxidant and the increased intracellular produc-
tion of NO and peroxynitrites can become cytotoxic
[49-55]. The close relationship these proteins have with
oxidative stress disease mechanisms suggests further
that oxidative stress is also a common and early factor
in these conditions. In summary, the present study
demonstrates for the first time that pathophysiology
resulting from diabetes and hyperglycemia substantially
increases the overall expression of PrP, Ab, SOD1 and
NOS1 & 2 proteins in diabetic muscle, and produces
localized accumulations of each of these proteins in
muscle fibers.
Conclusions
The present findings identify this well-characterized
model of diabetes and hyperglycemia in wild-type rab-
bits as a new and potentially important venue for simul-
taneously reproducing a range of hallmark pathological
features seen in a variety of muscle disease conditions
linked with different etiologies. The production of dia-
betes and hyperglycemia in otherwise normal rabbits
allows for normal physiological contributions by poten-
tially synergistic disease mechanisms associated with
Figure 4 PrP, Ab peptides, SOD1, NOS1 and NOS2 protein deposits accumulate in muscle fibers in diabetic rabbits. Above:
Immunohistochemical peroxidase detection of A: Ab peptides (mAb 6E10 Covance), B, C: PrP (rabbit mAb, Epitomics), D: NOS1 (mAb, BD
Biosciences), E: NOS2 (mAb, BD Biosciences), F: Superoxide dismutase 1 (Calbiochem), G: No primary antibody, normal control, H: No primary
antibody, diabetic muscle. Below: Immunofluorescence detection of proteins in diabetic muscle fibers. A: Ab (mAb 4G8, Covance), B: PrP (mAb,
Epitomics), C: overlay Ab & PrP staining, D: Brightfield micrograph of degenerating muscle fiber showing vacuoles around the perimeter, E:
Fluorescence photograph of anti-SOD1 staining in the same section as D, F: no primary antibody. Muscle fiber cross-sections are ~40-50 μm in
diameter. Images are representative of 3 diabetic and 3 control animals.
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amyloid and oxidative stress-related disease proteins
analyzed here. Our demonstration of increased expres-
sion and localized accumulations of these proteins in
diseased muscle that are more often associated with
neurodegenerative disease also has the potential to
inform about shared disease processes and potential
therapeutics that can affect brain as well as muscle.
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